RaminFarzaneh-FarMD
Cardiology • Dallas, TXAdult Congenital Heart Disease
Assistant Professor, Internal Medicine, University of Texas Southwestern Medical Center, Southwestern Medical School
Are you Dr. Farzaneh-Far?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 49 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
Ut Southwestern Medical Ctr
5323 Harry Hines Boulevard
Dallas, TX 75390Phone+1 214-645-7500
Summary
- Dr. Ramin Farzaneh-Far, MD is a cardiologist in Dallas, Texas. He is currently licensed to practice medicine in Texas and California. He is an Assistant Professor at University of Texas Southwestern Medical Center.
Education & Training
University of California (San Francisco)Fellowship, Cardiovascular Disease, 2006 - 2009
Brigham and Women's HospitalResidency, Internal Medicine, 2003 - 2005
Royal Free Hospital and University College London Medical SchoolClass of 2002
Certifications & Licensure
CA State Medical License 2006 - 2026
TX State Medical License 2011 - 2014
Clinical Trials
- Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease Start of enrollment: 2015 Dec 01
- Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) Start of enrollment: 2016 Feb 01
Publications & Presentations
PubMed
- 5 citationsPhase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria.Austin G Kulasekararaj, Anna-Elina Lehtinen, Cecily Forsyth, Shreyans Gandhi, Morag Griffin
Haematologica. 2024-03-01 - 19 citationsZilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial.Andrew L Mammen, Anthony A Amato, Mazen M Dimachkie, Hector Chinoy, Yessar Hussain
The Lancet. Rheumatology. 2023-02-01 - 37 citationsZilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis.James F. Howard, John Vissing, Nils Erik Gilhus, Maria Isabel Leite, Kimiaki Utsugisawa
Expert Opinion on Investigational Drugs. 2021-04-01
Press Mentions
Ra Pharmaceuticals Reports Second Quarter 2018 Financial Results and Announces Early Completion of Enrollment in gMG Phase 2 ProgramAugust 8th, 2018
Ra Pharmaceuticals Initiates Phase 1b Trial of New Therapy for Lupus NephritisJanuary 9th, 2018
